Kazia Therapeutics (KZIA) Notes Payables (2022 - 2025)

Kazia Therapeutics (KZIA) has disclosed Notes Payables for 4 consecutive years, with $253611.5 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Notes Payables fell 39.3% year-over-year to $253611.5, compared with a TTM value of $253611.5 through Jun 2025, down 39.3%, and an annual FY2025 reading of $256659.2, down 38.27% over the prior year.
  • Notes Payables was $253611.5 for Q2 2025 at Kazia Therapeutics, down from $417821.5 in the prior quarter.
  • Across five years, Notes Payables topped out at $1.2 million in Q2 2023 and bottomed at -$1.3 million in Q2 2022.
  • Average Notes Payables over 4 years is $138289.6, with a median of $335716.5 recorded in 2024.
  • The sharpest move saw Notes Payables skyrocketed 191.03% in 2023, then crashed 65.19% in 2024.
  • Year by year, Notes Payables stood at -$1.3 million in 2022, then surged by 191.03% to $1.2 million in 2023, then plummeted by 65.19% to $417821.5 in 2024, then crashed by 39.3% to $253611.5 in 2025.
  • Business Quant data shows Notes Payables for KZIA at $253611.5 in Q2 2025, $417821.5 in Q2 2024, and $1.2 million in Q2 2023.